ALX Oncology
ALXO
57 hedge funds and large institutions have $33.5M invested in ALX Oncology in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.
150% more call options, than puts
Call options by funds: $240K | Put options by funds: $96K
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
1.98% more ownership
Funds ownership: 51.89% → 53.87% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 61 → 57 (-4)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
35% less capital invested
Capital invested by funds: $51.3M → $33.5M (-$17.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.05M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$950K |
| 3 |
Millennium Management
New York
|
+$881K |
| 4 |
Renaissance Technologies
New York
|
+$392K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$232K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.19M |
| 2 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$932K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$103K |
| 4 |
JP Morgan Chase
New York
|
-$93.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$48.7K |
ALXO Hedge Fund Activity: Q4 2025 in Review
57 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2025, worth a combined $33.5M — down 35% from $51.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALXO and 8 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was UBS Group, adding an estimated $1.05M. The largest seller was Ameriprise, exiting entirely with an estimated $1.19M sold.
- 57 institutional investors held ALX Oncology (ALXO) as of Q4 2025, down from 61 in Q3 2025.
- Funds reported $33.5M of ALX Oncology stock for Q4 2025, down 35% quarter-over-quarter.
- 8 funds opened new ALX Oncology positions in Q4 2025 and 10 closed out, a net change of -2 holders.
- The largest ALX Oncology buyer in Q4 2025 was UBS Group, an estimated $1.05M added.
- The largest ALX Oncology seller in Q4 2025 was Ameriprise, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2025.